Warfarin
Warfarin - Related Videos
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
0 Views •
Cited by 49 •
2012
The accompanying video describes a procedure for percutaneous placement of the WATCHMAN Left Atrial Appendage (LAA) Device. The WATCHMAN is a nitinol device designed to be permanently implanted at, or slightly distal to, the opening of the left atrial appendage (LAA) to trap blood clots before they exit the LAA, preventing thromboembolic stroke.
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
0 Views •
Cited by 11 •
2013
Catheter ablation is combined with placement of the WATCHMAN Left Atrial Appendage Closure Device to prevent ischemic stroke in a patient with non-valvular atrial fibrillation.
06:31
Organocatalysis
0 Views •
2023
Source: Vy M. Dong and Faben Cruz, Department of Chemistry, University of California, Irvine, CA This experiment will demonstrate the concept of organocatalysis by illustrating the proper setup of a reaction that utilizes enamine catalysis. Organocatalysis is a form of catalysis that uses substoichiometric amounts of small organic molecules to accelerate reactions. This type of catalysis is complementary to other forms of catalysis such as transition metal or biocatalysis. Transition metal...
FAQs
Warfarin inhibits vitamin K epoxide reductase, the enzyme that regenerates active vitamin K. Without sufficient active vitamin K, the liver produces reduced amounts of clotting factors II, VII, IX, and X. This biochemical interruption explains why the drug changes coagulation through hepatic protein synthesis rather than by directly removing clotting factors already present in the blood.
The vitamin K pathway supports production of clotting factors II, VII, IX, and X as well as regulatory proteins C and S. Warfarin therefore alters several components of the coagulation system at once, rather than targeting a single clotting factor. This broad pharmacologic effect is important when interpreting its overall influence on thrombus formation and treatment response.
Diet, genetic differences, disease, and interactions with other drugs can all change the response to warfarin. These variables help explain why a dose that produces an appropriate effect in one patient may not do so in another. Pharmacology therefore treats dosing as individualized and links dose decisions to ongoing assessment with the international normalized ratio.
Clinicians select the dose for the individual patient and monitor its effect with the international normalized ratio, or INR. Monitoring provides a laboratory measure used to assess the anticoagulant response while factors such as diet, genetics, disease, and drug interactions may alter that response. This approach allows treatment decisions to account for patient-specific variability.
Warfarin is used to prevent and treat thromboembolic conditions, meaning problems caused by harmful blood clots moving or forming within the circulation. The overview specifically identifies stroke associated with atrial fibrillation and venous thromboembolism as clinical contexts. These applications connect its pharmacologic action to prevention of serious cardiovascular and vascular outcomes.
The international normalized ratio is important because warfarin’s effect varies substantially among patients and can change with diet, genetics, disease, or drug interactions. Regular assessment with the INR gives clinicians information for individualized management rather than relying on a fixed dose for everyone. In pharmacology, it represents the monitoring component required to guide therapy safely and effectively.